首页> 外文期刊>Bone marrow transplantation >Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.
【24h】

Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.

机译:强度降低的HLA匹配同胞同种异体干细胞移植后,难治性皮肤T细胞淋巴瘤的移植物抗淋巴瘤作用。

获取原文
获取原文并翻译 | 示例
       

摘要

Cutaneous T-cell lymphomas (CTCL) are rare diseases that, in their advanced stages or in transformation, have a poor prognosis. Autologous stem cell transplantation (Au-SCT) after high-dose therapy has yielded disappointing results. Allogeneic transplantation (allo-SCT) provides the potential advantage of an immune-mediated graft-versus-lymphoma (GVL) effect. Reduced-intensity allo-SCT potentially offers a GVL effect, but with diminished toxicity related to the induction regimen; however, published experience with this approach in CTCL is limited. We report a series of three patients (age 35-49) with advanced, refractory (n=2) or transformed (n=1) CTCL who underwent reduced-intensity allo-SCT in the context of active disease. All three survived the peri-transplant period and, despite later having disease relapse, all exhibited evidence of a GVL effect. Relapses of the disease were in the context of immune suppression for graft-versus-host disease (GVHD), and when immune suppression was reduced, responses were regained. A comparison is made of these results to those in a review of the published literature to date. We conclude that while a GVL can be achieved for CTCL with reduced-intensity allogeneic transplantation, the clinical benefits are short lived and novel approaches are required to obtain sustained remissions.
机译:皮肤T细胞淋巴瘤(CTCL)是罕见疾病,处于晚期或转化期,预后较差。大剂量治疗后的自体干细胞移植(Au-SCT)产生了令人失望的结果。同种异体移植(allo-SCT)提供了免疫介导的移植物抗淋巴瘤(GVL)效应的潜在优势。强度降低的异源SCT可能提供GVL效应,但与诱导方案相关的毒性降低;但是,在CTCL中使用此方法的已发布经验有限。我们报告了三例(35-49岁)晚期,难治性(n = 2)或转化(n = 1)CTCL的患者,这些患者在活动性疾病中接受了强度降低的异基因SCT。这三者均在移植前存活了下来,尽管后来疾病复发,但均表现出了GVL效应。该疾病的复发是在针对移植物抗宿主疾病(GVHD)的免疫抑制的背景下进行的,当免疫抑制降低时,反应得以恢复。将这些结果与迄今已发表文献的综述进行了比较。我们得出结论,尽管强度降低的同种异体移植可以为CTCL实现GVL,但临床益处是短暂的,需要新的方法来获得持续缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号